Biogen (BIIB) Long-Term Investments (2009 - 2026)

Biogen's Long-Term Investments history runs 17 years deep, the most recent figure standing at $465.6 million for Q1 2026.

• In Q1 2026, Long-Term Investments changed N/A year-over-year to $465.6 million; the TTM figure through Mar 2026 stood at $465.6 million (changed N/A YoY), while the FY2025 annual figure was $431.9 million, changed N/A from the prior year.
• Long-Term Investments was $465.6 million for Q1 2026 at Biogen, up from $431.9 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $1.2 billion in Q2 2023 to a low of $100000.0 in Q3 2023.
• Historically, Long-Term Investments has averaged $750.5 million across 4 years, with a median of $860.3 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Long-Term Investments gained 21.86% in 2022, then plunged 99.99% in 2023.
• A 4-year view of Long-Term Investments shows it stood at $705.7 million in 2022, then plunged by 99.99% to $100000.0 in 2023, then jumped by 431800.0% to $431.9 million in 2025, then grew by 7.8% to $465.6 million in 2026.
• The last three Long-Term Investments figures came in at $465.6 million (Q1 2026), $431.9 million (Q4 2025), and $100000.0 (Q3 2023), per Business Quant data.